Chee Keng Ng
About Chee Keng Ng
Chee Keng Ng is a Research Fellow at Akero Therapeutics, specializing in biotherapeutics and glycosylation. With over 15 years of experience in global CMC development, he has held various senior roles in prominent biotech companies such as Wyeth Biotech, Pfizer, and Orquest.
Current Role at Akero Therapeutics
Chee Keng Ng serves as a Research Fellow at Akero Therapeutics, a position he has held since 2019. His work is conducted in a home-based setting, allowing for flexibility while contributing to the company's research initiatives. In this role, he applies his extensive knowledge and experience in biotherapeutics to advance the company's projects.
Previous Experience in Biotech
Prior to his current position, Chee Keng Ng accumulated significant experience in the biotechnology sector. He worked at Pfizer as an Associate Research Fellow from 2011 to 2019, focusing on various aspects of biotherapeutics. Before that, he was a Senior Scientist at Orquest from 1997 to 2001 and spent nine years at Wyeth Biotech as a Senior Research Scientist II from 2001 to 2010.
Educational Background
Chee Keng Ng completed his undergraduate studies at Monash University, earning a Bachelor of Science with Honours and a Bachelor of Laws from 1984 to 1987. He furthered his education at Monash University Graduate School, where he obtained a PhD in Biochemistry from 1988 to 1992. He also completed his pre-university studies at Taylors College, achieving the South Australian Matriculation Examination in 1984.
Expertise in Biotherapeutics
Chee Keng Ng possesses over 15 years of experience in global Chemistry, Manufacturing, and Controls (CMC) development, encompassing both early and late-stage processes. His expertise includes biologics process and product development, analytical development, and characterization strategies. He is recognized as a subject matter expert in glycosylation control in mammalian expression systems and has a strong focus on glyco-immunology and effector function biology.
Contributions to Regulatory Submissions
Throughout his career, Chee Keng Ng has successfully progressed various regulatory submissions, including Investigational New Drug applications (IND), Clinical Trial Applications (CTA), and Biologics License Applications (BLA). He has developed content strategies for biosimilars and biotherapeutics, ensuring compliance with regulatory requirements and advancing product development.